The information provided on this site is intended only
for healthcare professionals (HCPs) in the United States.
Are you an HCP?
Because THYQUIDITY dosing depends on a variety of factors, doses must be individualized. Doses >200 mcg/day are seldom required. An inadequate response to doses >300 mcg/day is rare and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors.
Hypothyroidism
THYQUIDITY™ (levothyroxine sodium) oral solution is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
Pituitary Thyrotropin (Thyroid Stimulating Hormone, TSH) Suppression
THYQUIDITY is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
Limitations of Use
THYQUIDITY is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients, as there are no clinical benefits and over-treatment with THYQUIDITY may induce hyperthyroidism.
THYQUIDITY is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
Eligible patients may pay as little as $0 for THYQUIDITY*
*Offer valid for commercially insured patients only. Additional eligibility restrictions and terms and conditions apply.
Review factors that may impact the ability to achieve a clinical and biochemical euthyroid state
Explore how liquid THYQUIDITY allows you to offer individualized dosing designed to meet patients’ needs
THYQUIDITY™ (levothyroxine sodium) oral solution is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
THYQUIDITY is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
THYQUIDITY is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients, as there are no clinical benefits and over-treatment with THYQUIDITY may induce hyperthyroidism.
THYQUIDITY is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
Thyroid hormones, including THYQUIDITY, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
Please see full Prescribing Information including Boxed Warning.
REFERENCE: 1. THYQUIDITY (levothyroxine sodium) oral solution [package insert]. New Providence, NJ: Vertice Specialty Group: 12/2020.
THYQUIDITY™ (levothyroxine sodium) oral solution is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
THYQUIDITY is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
Thyroid hormones, including THYQUIDITY, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
The information provided on this site is intended only
for healthcare professionals (HCPs) in the United States.
Are you an HCP?
Coming Soon